Ofichem has unified its business divisions under a single brand identity, announcing that all operations will now trade under the Ofichem name. The move consolidates several long-standing brands — including Ofichem BV, Ofipharma, Ofimedicine, Labatorium Ofichem, Ofichem Uppsala, and Avivia — into one integrated organization.
The change, effective April 1, brings together Ofichem’s capabilities in drug substances, drug products, and pharmaceutical sourcing and distribution. The company said the unified structure is intended to simplify engagement with customers while maintaining existing quality standards, regulatory compliance, and points of contact.
According to CEO Weite Oldenziel, the consolidation reflects how Ofichem’s operations have evolved across the pharmaceutical development and manufacturing lifecycle. “Over time, we’ve built depth across API, drug substance, drug product, and supply,” Oldenziel said. “Combining all brands under the Ofichem umbrella makes that clearer as we continue to support customers in a more connected way.”
The transition does not affect legal entities, contracts, or ongoing services. Ofichem emphasized that customers will continue working with their established teams and systems.
By aligning its capabilities and communications under one identity, Ofichem aims to enhance visibility of its end-to-end CDMO offerings and strengthen its position as a European-based partner focused on reliability, regulatory expertise, and supply chain continuity in an increasingly complex global market.